- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Need More Justification: CDSCO Panel rejects J&J protocol amendment proposal for Teclistamab study
![Need More Justification: CDSCO Panel rejects J&J protocol amendment proposal for Teclistamab study Need More Justification: CDSCO Panel rejects J&J protocol amendment proposal for Teclistamab study](https://medicaldialogues.in/h-upload/2024/02/10/750x450_231958-johnson-and-johnson-50-1.webp)
New Delhi: Citing that more justification is required, the Subject Expert Committee SEC functional under the Central Drug Standard Control Organisation (CDSCO) has rejected Johnson & Johnson's protocol amendment proposal for the anti-cancer drug Teclistamab study.
This came after the firm presented protocol amendment 3.0 dated 14 June 2023 protocol No. 64007957MMY3005.
This is a study of Teclistamab in combination with Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in combination with Daratumumab and Lenalidomide (Tal-DR) in participants with newly diagnosed multiple myeloma (MajesTEC-7).
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Teclistamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager used to treat relapsed and refractory multiple myeloma in adults as monotherapy.
Teclistamab binds to a protein called CD3, which is found in T cells (a type of white blood cell). It also binds to a protein called BCMA, which is found on myeloma cells and some B cells (another type of white blood cell). This may help the immune system kill cancer cells.
At the recent SEC meeting for Oncology held on 21st February 2023, the expert panel reviewed the presented protocol amendment 3.0 dated 14 June 2023 protocol No. 64007957MMY3005.
After detailed deliberation, the committee opined that due to significant drug-related toxicity, the protocol amendment may not be considered at this stage and more justification is required to be submitted for further review by the committee.
Also Read: CDSCO panel Rejects Akum Pharma's FDC Bempedoic acid plus Atorvastatin Calcium plus Ezetimibe
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751